Methohexitone
Methohexitone Brand names, Methohexitone Analogs
Methohexitone Brand Names Mixture
- No information avaliable
Methohexitone Chemical_Formula
C14H18N2O3
Methohexitone RX_link
http://www.rxlist.com/cgi/generic3/methohexital.htm
Methohexitone fda sheet
Methohexitone msds (material safety sheet)
Methohexitone Synthesis Reference
No information avaliable
Methohexitone Molecular Weight
262.304 g/mol
Methohexitone Melting Point
No information avaliable
Methohexitone H2O Solubility
No information avaliable
Methohexitone State
Solid
Methohexitone LogP
1.724
Methohexitone Dosage Forms
Powder for solution
Methohexitone Indication
Indicated for use as an intravenous anaesthetic.
Methohexitone Pharmacology
Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Methohexitone Absorption
The absolute bioavailability following rectal administration of methohexital is 17%.
Methohexitone side effects and Toxicity
The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
Methohexitone Patient Information
When appropriate, patients should be instructed as to the hazards of drowsiness that may follow use of barbiturates. Outpatients should be released in the company of another individual, and no skilled activities, such as operating machinery or driving a motor vehicle, should be engaged in for 8 to 12 hours.
Methohexitone Organisms Affected
Humans and other mammals
